New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
25 sept. 2024 01h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials.
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
24 sept. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for scalp and body psoriasis.
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
19 sept. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
ZORYVE® (roflumilast) cream 0.15% improved atopic dermatitis (AD) across multiple efficacy endpoints while demonstrating favorable safety and tolerabilityAcross both studies, approximately 31% of...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 sept. 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
05 sept. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the enrollment of the last subject in the Phase 1b study evaluating ARQ-255 for the treatment of alopecia areata.
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
28 août 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced results from the INTEGUMENT-OLE long-term open-label study of once-daily roflumilast cream 0.05%.
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
22 août 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that management will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference.
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 21h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update.
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 août 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...